B F Gage

Summary

Affiliation: Washington University School of Medicine
Country: USA

Publications

  1. ncbi request reprint Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin
    Brian F Gage
    Department of Medicine, Washington University School of Medicine Campus Box 8005, 660 S Euclid Ave St Louis, Missouri 63110, USA
    Thromb Haemost 91:87-94. 2004
  2. ncbi request reprint Pharmacology and pharmacogenetics of warfarin and other coumarins when used with supplements
    Brian F Gage
    Division of General Medical Sciences, Washington University School of Medicine, Campus Box 8005, 660 S Euclid, St Louis, MO 63110, USA
    Thromb Res 117:55-9; discussion 65-7. 2005
  3. ncbi request reprint Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall
    Brian F Gage
    Division of General Medical Sciences, Washington University School of Medicine, St Louis, MO, USA
    Am J Med 118:612-7. 2005
  4. ncbi request reprint Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2
    Brian F Gage
    Division of General Medical Sciences, Washington University School of Medicine, St Louis, MO 63110, USA
    Arch Intern Med 166:241-6. 2006
  5. ncbi request reprint Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF)
    Brian F Gage
    Division of General Medical Sciences, Washington University School of Medicine, St Louis, MO 63110, USA
    Am Heart J 151:713-9. 2006
  6. ncbi request reprint Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin
    Brian F Gage
    Division of General Medical Sciences, Washington University School of Medicine Campus Box 8005, 660 S Euclid Ave, St Louis, MO 63110, USA
    Circulation 110:2287-92. 2004
  7. ncbi request reprint Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues
    Brian F Gage
    Washington University Medical Center, St Louis, MO 63110, USA
    J Thromb Thrombolysis 25:45-51. 2008
  8. pmc Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin
    B F Gage
    Department of Internal Medicine, Washington University School of Medicine, St Louis, Missouri, USA
    Clin Pharmacol Ther 84:326-31. 2008
  9. ncbi request reprint Pharmacogenetics and anticoagulant therapy
    Brian F Gage
    Division of General Medical Sciences, Washington University School of Medicine, St Louis, MO 63110, USA
    J Thromb Thrombolysis 16:73-8. 2003
  10. doi request reprint Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation
    Shimoli V Shah
    Department of Medicine, Washington University School of Medicine, Campus Box 8005, 660 S Euclid Ave, St Louis, MO 63110, USA
    Circulation 123:2562-70. 2011

Research Grants

  1. Pharmacogenetics and Antithrombotic Therapy
    Brian Gage; Fiscal Year: 2003

Collaborators

Detail Information

Publications61

  1. ncbi request reprint Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin
    Brian F Gage
    Department of Medicine, Washington University School of Medicine Campus Box 8005, 660 S Euclid Ave St Louis, Missouri 63110, USA
    Thromb Haemost 91:87-94. 2004
    ..001). In conclusion, the maintenance warfarin dose can be estimated from demographic, clinical, and pharmacogenetic factors that can be obtained at the time of warfarin initiation...
  2. ncbi request reprint Pharmacology and pharmacogenetics of warfarin and other coumarins when used with supplements
    Brian F Gage
    Division of General Medical Sciences, Washington University School of Medicine, Campus Box 8005, 660 S Euclid, St Louis, MO 63110, USA
    Thromb Res 117:55-9; discussion 65-7. 2005
  3. ncbi request reprint Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall
    Brian F Gage
    Division of General Medical Sciences, Washington University School of Medicine, St Louis, MO, USA
    Am J Med 118:612-7. 2005
    ..Patients at high risk for falls are presumed to be at increased risk for intracranial hemorrhage, and high risk for falls is cited as a contraindication to antithrombotic therapy. Data substantiating this concern are lacking...
  4. ncbi request reprint Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2
    Brian F Gage
    Division of General Medical Sciences, Washington University School of Medicine, St Louis, MO 63110, USA
    Arch Intern Med 166:241-6. 2006
    ..Vitamin K antagonists such as warfarin inhibit this process. Our goal was to quantify the association between warfarin and osteoporotic fractures in patients with atrial fibrillation...
  5. ncbi request reprint Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF)
    Brian F Gage
    Division of General Medical Sciences, Washington University School of Medicine, St Louis, MO 63110, USA
    Am Heart J 151:713-9. 2006
    ..Our objective was to find a bleeding classification scheme that could quantify the risk of hemorrhage in elderly patients with atrial fibrillation...
  6. ncbi request reprint Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin
    Brian F Gage
    Division of General Medical Sciences, Washington University School of Medicine Campus Box 8005, 660 S Euclid Ave, St Louis, MO 63110, USA
    Circulation 110:2287-92. 2004
    ..This prospective cohort study tested the predictive accuracy of 5 stroke risk stratification schemes...
  7. ncbi request reprint Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues
    Brian F Gage
    Washington University Medical Center, St Louis, MO 63110, USA
    J Thromb Thrombolysis 25:45-51. 2008
    ..The FDA completed the label update in August 2007...
  8. pmc Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin
    B F Gage
    Department of Internal Medicine, Washington University School of Medicine, St Louis, Missouri, USA
    Clin Pharmacol Ther 84:326-31. 2008
    ..To facilitate use of these pharmacogenetic and clinical algorithms, we developed a nonprofit website, http://www.WarfarinDosing.org...
  9. ncbi request reprint Pharmacogenetics and anticoagulant therapy
    Brian F Gage
    Division of General Medical Sciences, Washington University School of Medicine, St Louis, MO 63110, USA
    J Thromb Thrombolysis 16:73-8. 2003
    ..Thus, a comprehensive dosing algorithm offers the most promising approach to estimating the therapeutic dose of warfarin a priori and to preventing hemorrhage during warfarin induction...
  10. doi request reprint Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation
    Shimoli V Shah
    Department of Medicine, Washington University School of Medicine, Campus Box 8005, 660 S Euclid Ave, St Louis, MO 63110, USA
    Circulation 123:2562-70. 2011
    ..Recent studies have investigated alternatives to warfarin for stroke prophylaxis in patients with atrial fibrillation (AF), but whether these alternatives are cost-effective is unknown...
  11. ncbi request reprint Warfarin therapy for an octogenarian who has atrial fibrillation
    B F Gage
    Division of General Medical Science, Washington University School of Medicine, Campus Box 8005, 660 South Euclid Avenue, St Louis, MO 63110, USA
    Ann Intern Med 134:465-74. 2001
    ..Finally, when the patient develops dental pain, we review the analgesic agents that are safe to take with warfarin and explain why warfarin therapy does not have to be interrupted during a subsequent dental extraction...
  12. ncbi request reprint Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation
    B F Gage
    Division of General Medical Sciences, Washington University School of Medicine Campus, Box 8005, 660 S Euclid Ave, St Louis, MO 63110, USA
    JAMA 285:2864-70. 2001
    ..Patients who have atrial fibrillation (AF) have an increased risk of stroke, but their absolute rate of stroke depends on age and comorbid conditions...
  13. pmc Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy
    N S Ferder
    Saint Louis College of Pharmacy, St Louis, MO, USA
    J Thromb Haemost 8:95-100. 2010
    ..Experts have hypothesized that genotype becomes irrelevant once international normalized ratio (INR) values are available because INR response reflects warfarin sensitivity...
  14. pmc A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans
    D Voora
    Department of Medicine, Washington University in St Louis, St Louis, Missouri, USA
    Clin Pharmacol Ther 87:445-51. 2010
    ..14, one-sided P = 0.03). CALU rs339097 A>G is associated with higher warfarin dose requirements, independent of known genetic and nongenetic predictors of warfarin dose in African Americans...
  15. pmc Integration of genetic, clinical, and INR data to refine warfarin dosing
    P Lenzini
    Department of Internal Medicine, Washington University, St Louis, Missouri, USA
    Clin Pharmacol Ther 87:572-8. 2010
    ..002). After several days of therapy, a pharmacogenetic algorithm estimates the therapeutic warfarin dose more accurately than one using clinical factors and INR response alone...
  16. pmc Patient and physician satisfaction with a telephone-based anticoagulation service
    A D Waterman
    Division of General Medical Sciences, Washington University School of Medicine, St Louis, MO 63110, USA
    J Gen Intern Med 16:460-3. 2001
    ..To compare the satisfaction and knowledge of patients who have their warfarin managed by their physician or by a multidisciplinary, telephone-based anticoagulation service (ACS) and to assess referring physicians' satisfaction with the ACS...
  17. ncbi request reprint Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype
    Deepak Voora
    Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Thromb Haemost 93:700-5. 2005
    ..Prospective, perioperative pharmacogenetics-based dosing of warfarin is feasible; however, further evaluation in a randomized, controlled study is recommended...
  18. pmc Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design
    E J Do
    Department of Internal Medicine, Washington University, St Louis, MO, USA
    Pharmacogenomics J 12:417-24. 2012
    ....
  19. ncbi request reprint Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation
    B F Gage
    Division of General Medical Sciences, Washington University, St Louis, MO, USA
    Stroke 29:1083-91. 1998
    ..The preference-based strategy prescribed whichever antithrombotic therapy, warfarin or aspirin, had the greater projected quality-adjusted survival...
  20. ncbi request reprint Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation
    Elena Birman-Deych
    Washington University School of Medicine, St Louis, MO 63110, USA
    Stroke 37:1070-4. 2006
    ..Our goal was to quantify use of warfarin therapy, frequency of International Normalized Ratio monitoring, and effectiveness for stroke prophylaxis in Medicare beneficiaries with atrial fibrillation...
  21. pmc Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients
    P A Lenzini
    Department of Internal Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    J Thromb Haemost 6:1655-62. 2008
    ..Warfarin is commonly prescribed for prophylaxis and treatment of thromboembolism after orthopedic surgery. During warfarin initiation, out-of-range International Normalized Ratio (INR) values and adverse events are common...
  22. ncbi request reprint The pharmacogenetics of coumarin therapy
    Deepak Voora
    Washington University School of Medicine, Departments of Medicine and of Pathology, St Louis, MO 63110, USA
    Pharmacogenomics 6:503-13. 2005
    ..A comprehensive pharmacogenetics approach to warfarin therapy has the potential to improve the safety and efficiency of warfarin initiation...
  23. doi request reprint Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose
    Cristi R King
    Department of Internal Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Am J Clin Pathol 129:876-83. 2008
    ..Current commercial platforms provide accurate and rapid genotypes for pharmacogenetic dosing during initiation of warfarin therapy...
  24. ncbi request reprint Comorbidity indices to predict mortality from Medicare data: results from the national registry of atrial fibrillation
    Yan Yan
    Division of General Medical Sciences, Washington University School of Medicine, St Louis, MO 63110, USA
    Med Care 43:1073-7. 2005
    ..By accounting for level of comorbidity, risk-adjustment models should quantify the risk of death. How accurately comorbidity indices predict risk of death in Medicare beneficiaries with atrial fibrillation is unclear...
  25. ncbi request reprint Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation
    B F Gage
    Division of General Medical Sciences, Washington University School of Medicine, St Louis, MO 63110, USA
    Stroke 31:822-7. 2000
    ....
  26. ncbi request reprint Substitution of generic warfarin for Coumadin in an HMO setting
    Paul E Milligan
    Division of General Medical Sciences, Barnes Jewish Hospital Blood Thinner Clinic, School of Medicine, Washington University, 660 S Euclid Avenue, St Louis, MO 63110 1093, USA
    Ann Pharmacother 36:764-8. 2002
    ..Substitution of generic warfarin for Coumadin presents safety concerns due to warfarin's narrow therapeutic index and because a prior generic formulation was removed from the US market after it was associated with adverse events...
  27. pmc Genetic-based dosing in orthopedic patients beginning warfarin therapy
    Eric A Millican
    Department of Medicine, Washington University in St Louis, MO 63110, USA
    Blood 110:1511-5. 2007
    ..If validated, this model should provide a safer, more effective process for initiating warfarin therapy...
  28. pmc Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score
    Sumeet Subherwal
    Cardiovascular Division, Washington University School of Medicine, St Louis, MO 63110, USA
    Circulation 119:1873-82. 2009
    ..Baseline prediction of bleeding risk can complement ischemic risk prediction for optimization of NSTEMI care; however, existing models are not well suited for this purpose...
  29. ncbi request reprint Optimal initial dose adjustment of warfarin in orthopedic patients
    Petra A Lenzini
    Washington University in St Louis, St Louis, MO 63110, USA
    Ann Pharmacother 41:1798-804. 2007
    ..Dosing algorithms have not been widely adopted because they require a fixed initial warfarin dose (eg, 5 mg) and are not tailored to other factors that may affect the international normalized ratio (INR)...
  30. doi request reprint Risk of stroke after surgery in patients with and without chronic atrial fibrillation
    S Kaatz
    Department of Medicine, Henry Ford Hospital, Detroit, MI 48202, USA
    J Thromb Haemost 8:884-90. 2010
    ..The extent to which chronic atrial fibrillation affects the risk of postoperative stroke is largely unknown...
  31. ncbi request reprint Establishing and running an effective telephone-based anticoagulation service
    A D Waterman
    Division of General Medical Sciences, Washington University School of Medicine, St Louis, MO 63110, USA
    J Vasc Nurs 19:126-32; quiz 133-4. 2001
    ....
  32. ncbi request reprint The impact of the introduction of a rapid D-dimer assay on the diagnostic evaluation of suspected pulmonary embolism
    N M Goldstein
    Campus Box 8052, Washington University School of Medicine, 660 S Euclid Ave, St Louis, MO 63110, USA
    Arch Intern Med 161:567-71. 2001
    ..Although this hypothesis is anticipated to decrease the use of ventilation-perfusion (VQ) scans and other diagnostic tests for PE, it has not been tested in a "real-world" environment...
  33. ncbi request reprint An invasive strategy is associated with decreased mortality in patients 80 years and older with acute myocardial infarction
    Timothy W Schloss
    Cardiovascular Division, Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Am J Geriatr Cardiol 16:84-91. 2007
    ..These data suggest that in patients 80 years and older who are hospitalized with acute myocardial infarction, an invasive strategy confers a significant survival advantage during the first year after hospital discharge...
  34. ncbi request reprint Reliability for grading acute rejection and airway inflammation after lung transplantation
    Murali M Chakinala
    Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Heart Lung Transplant 24:652-7. 2005
    ..This investigation assessed the reliability of the current LRSG system by determining inter- and intrareader agreement for grading transbronchial biopsy samples from lung transplant recipients...
  35. ncbi request reprint Effect of warfarin nonadherence on control of the International Normalized Ratio
    Amy D Waterman
    Division of General Medical Sciences, School of Medicine, Washington University, Campus Box 8005, 660 S Euclid, St Louis, MO 63110, USA
    Am J Health Syst Pharm 61:1258-64. 2004
    ..The frequency and causes of ab- errant International Normalized Ratios (INRs) in warfarin recipients and the percentage explainable by warfarin nonadherence were studied...
  36. ncbi request reprint Yield of surveillance bronchoscopy for acute rejection and lymphocytic bronchitis/bronchiolitis after lung transplantation
    Murali M Chakinala
    Division of Pulmonary and Critical Care Medicine, Saint Louis, Missouri 63110, USA
    J Heart Lung Transplant 23:1396-404. 2004
    ....
  37. ncbi request reprint Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation
    Cara L O'Brien
    Washington University School of Medicine, St Louis, MO 63110, USA
    JAMA 293:699-706. 2005
    ..Because ximelagatran can be taken in a fixed, oral dose without international normalized ratio monitoring and may have a lower risk of hemorrhage, it might improve quality-adjusted survival compared with dose-adjusted warfarin...
  38. ncbi request reprint Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors
    Elena Birman-Deych
    Division of General Medical Sciences, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Med Care 43:480-5. 2005
    ..We sought to determine which ICD-9-CM codes in Medicare Part A data identify cardiovascular and stroke risk factors...
  39. ncbi request reprint Use of pharmacogenetics to guide warfarin therapy
    Deepak Voora
    Departments of Medicine and Pathology, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Drugs Today (Barc) 40:247-57. 2004
    ..The genotype assays for genetic variants relevant to warfarin are widely used and are being developed for commercial use (5), making the promise of a pharmacogenetics-based approach a near reality...
  40. doi request reprint Anemia: an independent predictor of death and hospitalizations among elderly patients with atrial fibrillation
    Shivak Sharma
    Washington University in St Louis School of Medicine Barnes Jewish Hospital, St Louis, MO, USA
    Am Heart J 157:1057-63. 2009
    ..Anemia is an independent predictor of mortality and morbidity for numerous cardiovascular and noncardiovascular diseases, but the association of anemia with mortality and hospitalizations in patients with AF requires clarification...
  41. ncbi request reprint Outpatient treatment of acute venous thromboembolic disease
    Roger D Yusen
    Division of Pulmonary and Critical Care Medicine, Division of General Medical Sciences, Washington University School of Medicine, Barnes Jewish Hospital, 660 South Euclid Avenue, St Louis, MO 63110, USA
    Clin Chest Med 24:49-61. 2003
    ..Explicit criteria exist for outpatient DVT therapy. Home therapy for PE requires further evaluation before it can be recommended outside of a trial or other supervised setting...
  42. ncbi request reprint Simplified peak power reserve in patients with an implantable cardioverter-defibrillator and advanced heart failure
    William T Katsiyiannis
    Cardiovascular Division, Department of Internal Medicine, Washington University School of Medicine, St Louis, Missouri
    Am J Cardiol 95:286-8. 2005
    ..Reduced SPP reserve identified patients who are at high risk for experiencing progressive HF...
  43. ncbi request reprint Predictors of mortality in younger and older patients with heart failure and preserved or reduced left ventricular ejection fraction
    Roger Kerzner
    Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Am Heart J 146:286-90. 2003
    ..Although half of elderly patients with heart failure have preserved left ventricular ejection fraction (LVEF), little is known about predictors of mortality in this group...
  44. ncbi request reprint Risk factors for bleeding in patients taking coumarins
    Rebecca J Beyth
    Division of General Medical Sciences, Washington University School of Medicine, Campus Box 8005, 660 S Euclid Avenue, St Louis, MO 63110, USA
    Curr Hematol Rep 1:41-9. 2002
    ..During ongoing therapy with coumarins, the risks and benefits of therapy should be reassessed periodically. This article reviews the current evidence for the prediction and prevention of coumarin-related bleeding...
  45. ncbi request reprint Cost-savings analysis of using a portable coagulometer for monitoring homebound elderly patients taking warfarin
    Dorothy S Cheung
    Division of General Medical Sciences, Washington University School of Medicine, St Louis, MO 63110, USA
    Am J Geriatr Cardiol 12:283-7. 2003
    ..The cost savings and potential improvement in quality of care argue for equipping home health nurses with portable coagulometers...
  46. ncbi request reprint Warfarin dose reduction vs watchful waiting for mild elevations in the international normalized ratio
    Gerald A Banet
    Division of General Medical Sciences, Washington University School of Medicine, St Louis, MO 63110, USA
    Chest 123:499-503. 2003
    ..Whether clinicians should decrease the warfarin dose in response to a mild, asymptomatic elevation in the international normalized ratio (INR) is unknown...
  47. ncbi request reprint Implantable cardioverter-defibrillator therapy improves long-term survival in patients with unexplained syncope, cardiomyopathy, and a negative electrophysiologic study
    José Mauricio Sánchez
    Cardiovascular Division, Department of Internal Medicine, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Heart Rhythm 2:367-73. 2005
    ..The purpose of this study was to evaluate the long-term outcomes of patients with unexplained syncope, ischemic or nonischemic cardiomyopathy, and a negative electrophysiologic study (EPS)...
  48. ncbi request reprint Use of EPO in critically ill patients with acute renal failure requiring renal replacement therapy
    Jeanie Park
    Division of General Medical Sciences, Department of Internal Medicine, Washington University, St Louis, MO 63110, USA
    Am J Kidney Dis 46:791-8. 2005
    ..In vitro and animal studies suggest that EPO may promote renal recovery and decrease mortality in ARF...
  49. doi request reprint Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients
    T F Wang
    Brian F Gage, MD, 660 South Euclid Ave, Campus Box 8005, Department of Medicine, Washington University School of Medicine, Saint Louis, MO 63110, USA Tel 1 314 454 8697, Fax 1 314 454 5554 E mail
    Thromb Haemost 111:88-93. 2014
    ..84, 95% CI 0.66-1.07, p = 0.15). Independent predictors of VTE were surgery, male sex, cancer, and BMI. In conclusion, high-dose thromboprophylaxis nearly halves the rate of VTE in morbidly obese inpatients. ..
  50. ncbi request reprint Criteria for outpatient management of proximal lower extremity deep venous thrombosis
    R D Yusen
    Department of Medicine, Barnes Jewish Hospital, Washington University School of Medicine, St Louis, MO 63110, USA
    Chest 115:972-9. 1999
    ..To develop and to evaluate selection criteria for outpatient management of deep venous thrombosis (DVT)...
  51. ncbi request reprint Anemia does not predict mortality in elderly patients with heart failure
    Roger Kerzner
    Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Am J Geriatr Cardiol 16:92-6. 2007
    ..The authors conclude that anemia is not an important predictor of long-term survival in very elderly patients hospitalized with HF...
  52. ncbi request reprint Cost-effectiveness of extending Medicare coverage of immunosuppressive medications to the life of a kidney transplant
    Eugene F Yen
    Department of Internal Medicine, Washington University School of Medicine, St Louis, MO, USA
    Am J Transplant 4:1703-8. 2004
    ..Extended Medicare immunosuppression coverage to the life of a kidney transplant should result in better transplant and economic outcomes, and should be considered by policy makers...
  53. ncbi request reprint Perioperative reduction of the warfarin dose
    Paul E Milligan
    Am J Med 115:741-2. 2003
  54. ncbi request reprint Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose
    Mark J Rieder
    Department of Genome Sciences, University of Washington, Seattle, USA
    N Engl J Med 352:2285-93. 2005
    ..The management of warfarin therapy is complicated by a wide variation among patients in drug response. Variants in the gene encoding vitamin K epoxide reductase complex 1 (VKORC1) may affect the response to warfarin...
  55. ncbi request reprint Randomized trial of warfarin nomograms
    Brian F Gage
    Ann Intern Med 140:489; author reply 491-2. 2004
  56. ncbi request reprint Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified?
    Lawrence Baruch
    Bronx VA Hospital, Bronx, NY 10468, USA
    Stroke 38:2459-63. 2007
    ..The objective of this study was to assess the predictive value of stroke risk classification schemes and to identify patients with atrial fibrillation who are at substantial risk of stroke despite optimal anticoagulant therapy...
  57. ncbi request reprint The management of anticoagulants in the periendoscopic period for patients with atrial fibrillation: a decision analysis
    Lauren B Gerson
    Division of Gastroenterology, Stanford University School of Medicine, California 94305 5202, USA
    Am J Med 116:451-9. 2004
    ..The management of patients who undergo endoscopy while being treated with warfarin is challenging. We used decision analysis to determine the preferred strategy to manage anticoagulants in the periendoscopic period...
  58. ncbi request reprint Preference-based antithrombotic therapy in atrial fibrillation: implications for clinical decision making
    Malcolm Man-Son-Hing
    Elisabeth Bruyere Research Institute and Division of Geriatric Medicine, University of Ottawa, Ottawa, Ontario, Canada
    Med Decis Making 25:548-59. 2005
    ..The authors compared the thresholds for antithrombotic treatment from studies that determined or modeled the treatment preferences of patients with atrial fibrillation with recommendations from clinical practice guidelines...
  59. pmc CYP4F2 genetic variant alters required warfarin dose
    Michael D Caldwell
    Department of Surgery, Marshfield Clinic, Marshfield, WI, USA
    Blood 111:4106-12. 2008
    ..Genetic variation of CYP4F2 was associated with a clinically relevant effect on warfarin requirement...
  60. ncbi request reprint Is primary care ready for pharmacogenetics?
    Deepak Voora
    Pharmacogenomics 7:1-3. 2006

Research Grants1

  1. Pharmacogenetics and Antithrombotic Therapy
    Brian Gage; Fiscal Year: 2003
    ..Using high performance liquid chromatography, we will measure the levels of the 2 enantiomers of warfarin and test Hypothesis 4: Clearance of S-warfarin will be significantly decreased in the presence of 2C9 SNPs. ..